Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds

Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) completed the third and final closing of exercises of outstanding preferred investment options, issuing a total of 13,989,115 shares of common stock and raising approximately $29.2 million in gross proceeds across three closings ($25.2M, $1.2M, $2.8M) prior to fees.

The company issued new unregistered short-term Series J preferred investment options to purchase up to the same 13,989,115 shares with an $4.50 exercise price, exercisable beginning six months after issuance for a two-year term, representing potential additional gross proceeds of approximately $63 million if fully exercised. H.C. Wainwright acted as placement agent. Net proceeds are intended for LIBERTY robotic system development, regulatory and commercialization activities, potential acquisitions, IP applications, and working capital.

Positive

• Gross proceeds raised: $29.2M across three closings
• Issued 13,989,115 common shares upon option exercises
• Series J options could provide ~$63M additional proceeds if exercised
• Series J exercise price set at $4.50, exercisable after 6 months

Negative

• Series J options are unregistered and may never be exercised
• Initial gross proceeds are prior to placement agent fees and expenses
• Potential dilution if up to 13,989,115 Series J shares are exercised

Insights

Capital Markets Strategist

Company raised roughly $29.2 million now and can access up to $63 million more if new options are exercised.

The financing converted exercised preferred investment options into 13,989,115 newly issued common shares in three closings, generating gross proceeds of approximately $25.2 million, $1.2 million, and $2.8 million respectively. In exchange the company issued new unregistered short-term series J preferred investment options exercisable at $4.50 per share beginning six months after issuance and expiring two years later; full exercise would yield approximately $63 million in additional gross proceeds.

The immediate business effect is increased cash on the balance sheet and a clear path to potential additional funding without immediate dilution from the series J options. Key dependencies and risks are explicit: the additional $63 million is contingent on option holders choosing to exercise, and the series J options were sold under a private placement and are unregistered until the company files the resale registration statement. Watch for the company's filing and the six‑month exercise window as near-term liquidity and dilution milestones over the next six months to two years.

$25.2 million in first closing, $1.2 million in second closing and $2.8 million in third and final closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options

HINGHAM, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) (“Microbot” or the “Company”), today announced the third and final closing of its previously announced exercise of certain outstanding preferred investment options to purchase an aggregate of 13,989,115 shares of common stock. The shares of common stock issuable upon exercise of the preferred investment options are registered pursuant to the post-effective amendments on Form S-3 to registration statements on Form S-1 (File Nos. 333-280113 and 333-284688) and registration statement on Form S-3 (File No. 333-285690).

The closing of the offering occurred in three tranches. At the first closing, the holders exercised certain outstanding preferred investment options to purchase an aggregate of 12,064,627 shares of common stock, having exercise prices ranging from $1.50 to $2.13 per share, issued by Microbot in June 2024, January 2025 and February 2025, and in consideration for the exercise of the preferred investment options for cash, Microbot issued to such holders new unregistered short-term series J preferred investment options to purchase up to 12,064,627 shares of common stock. At the second closing, a holder exercised certain outstanding preferred investment options to purchase an aggregate of 600,000 shares of common stock, having an exercise price of $2.10 per share, issued by Microbot in January 2025, and in consideration for the exercise of the preferred investment options for cash, Microbot issued to such holder new unregistered short-term series J preferred investment options to purchase up to 600,000 shares of common stock. At the third and final closing, a holder exercised certain outstanding preferred investment options to purchase an aggregate of 1,324,488 shares of common stock, having an exercise price of $2.10 per share, issued by Microbot in January 2025, and in consideration for the exercise of the preferred investment options for cash, Microbot issued to such holder new unregistered short-term series J preferred investment options to purchase up to 1,324,488 shares of common stock. The new short-term series J preferred investment options will have an exercise price of $4.50 per share, will be exercisable beginning six months after issuance and have a term equal to two years thereafter.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The gross proceeds to the Company were approximately $25.2 million from the first closing of the offering, approximately $1.2 million from the second closing of the offering and approximately $2.8 million from the third and final closing of the offering, in each case prior to deducting placement agent fees and offering expenses. The potential additional gross proceeds to the Company from the short-term series J preferred investment options, if fully-exercised on a cash basis, will be approximately $63 million.  No assurance can be given that any of such short-term series J preferred investment options will be exercised.  The Company intends to use the net proceeds from the offering for the continued development, commercialization and regulatory activities for the Company’s LIBERTY^® Robotic System, potential acquisitions of complementary assets or products, expansion and development of additional applications derived from the Company’s existing IP portfolio, and for working capital and other general corporate purposes.

The new short-term series J preferred investment options described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”), and, along with the shares of common stock issuable upon exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. Microbot has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new short-term series J preferred investment options.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a breakthrough medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, the exercise of the unregistered short-term series J preferred investment options prior to their expiration, the intended use of proceeds from the offering, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:

IR@microbotmedical.com
Media@microbotmedical.com

FAQ

What did Microbot Medical (MBOT) announce on October 7, 2025 about option exercises?

Microbot announced final closing of option exercises issuing 13,989,115 shares and raising about $29.2M in gross proceeds across three closings.

How much additional capital could Microbot (MBOT) raise from the new Series J options?

If fully exercised on a cash basis, the Series J preferred investment options could generate approximately $63 million of additional gross proceeds.

What are the terms of the new Series J preferred investment options for MBOT?

Series J options have an $4.50 exercise price, become exercisable six months after issuance, and expire two years thereafter.

How did Microbot (MBOT) receive the initial proceeds and who acted as placement agent?

Gross proceeds of approximately $25.2M, $1.2M, and $2.8M were received in three closings, with H.C. Wainwright as exclusive placement agent.

What will Microbot (MBOT) use the net proceeds for?

The company intends to use net proceeds for LIBERTY robotic system development, commercialization and regulatory activities, potential acquisitions, IP application development, and working capital.